Chaber Radosław, Łasecki Mateusz, Kwaśnicka Justyna, Łach Kornelia, Podgajny Zbigniew, Olchowy Cyprian, Zaleska-Dorobisz Urszula
Department of Pediatric Oncology and Hematology, Faculty of Medicine, University of Rzeszów, Poland.
Department of General and Pediatric Radiology, Wroclaw Medical University, Poland.
Adv Clin Exp Med. 2018 Jun;27(6):795-805. doi: 10.17219/acem/68990.
The precise identification of the primarily-affected nodal regions in Hodgkin's lymphoma(HL) is essential in determining the stage of the disease and the intensity of chemotherapy and radiotherapy.
The aim of this study was to use the degree of X-ray attenuation (XRA) in Hounsfield units(HU) and the lymph node-to-muscle attenuation ratio (LN/M) in computed tomography (CT) unenhancedimaging, routinely performed with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET),to distinguish HL-affected supradiaphragmatic lymph nodes.
The study included 52 patients with classical HL treated according to the EuroNet-PHL-C1 protocol. Patients received 2 chemotherapy cycles after 18F-FDG-PET/CT testing, followedby re-examination. The lymph nodes were evaluated according to the Society for Pediatric Oncology andHematology's GPOH-HD-2002 study and Lugano criteria as not-involved (NI-LN) and involved (I-LN).
A significant difference (p < 0.001) was found in the XRA and LN/M values between NI-LN andI-LN before treatment and after the 2 chemotherapy cycles. The optimal cut-off point for XRA (44.7 HU) andLN/M (0.79) values distinguishing I-LN from NI-LN nodes was determined by receiver operating characteristic(ROC) analysis. After 2 cycles of chemotherapy, higher XRA (p = 0.002) and LN/M (p = 0.001) values in thegroup with inadequate early CTx response were found.
The use of XRA in HU and LN/M, together with the existing standard, can improve the qualificationof supradiaphragmatic lymph nodes in HL.
准确识别霍奇金淋巴瘤(HL)中主要受累的淋巴结区域对于确定疾病分期以及化疗和放疗强度至关重要。
本研究旨在利用计算机断层扫描(CT)平扫成像中以亨氏单位(HU)表示的X线衰减程度(XRA)以及淋巴结与肌肉的衰减比(LN/M),这种成像通常与18F-氟脱氧葡萄糖正电子发射断层扫描(18F-FDG-PET)一起进行,以区分HL累及的膈上淋巴结。
该研究纳入了52例根据EuroNet-PHL-C1方案治疗的经典HL患者。患者在进行18F-FDG-PET/CT检查后接受2个化疗周期,随后进行复查。根据儿科肿瘤学和血液学协会的GPOH-HD-2002研究及卢加诺标准,将淋巴结评估为未受累(NI-LN)和受累(I-LN)。
治疗前及2个化疗周期后,NI-LN和I-LN的XRA及LN/M值存在显著差异(p < 0.001)。通过受试者操作特征(ROC)分析确定了区分I-LN与NI-LN淋巴结的XRA(44.7 HU)和LN/M(0.79)值的最佳截断点。化疗2个周期后,早期CTx反应不足组的XRA(p = 0.002)和LN/M(p = 0.001)值更高。
将HU中的XRA和LN/M与现有标准结合使用,可改善HL中膈上淋巴结的定性。